What one share of Ligand Pharmaceuticals Incorporated holds
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
Ligand Pharmaceuticals Incorporated’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $13.56 |
|---|---|
| Profit | $9.20 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $6.13 |
| Cash and investments | $50.54 |
| Debt | $56.56 |
| Book value | $48.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $2.06 | −$0.10 | $0.03 | −$1.82 | — | $0.20 |
| 2010 | $1.20 | −$0.53 | $0.00 | −$1.38 | — | −$0.25 |
| 2011 | $1.52 | $0.49 | $0.00 | −$0.06 | — | $0.40 |
| 2012 | $1.58 | −$0.03 | $0.03 | −$0.02 | — | $1.24 |
| 2013 | $2.36 | $0.55 | $0.02 | $0.98 | — | $2.42 |
| 2014 | $3.01 | $0.56 | $0.00 | $0.96 | — | $1.34 |
| 2015 | $3.39 | $10.83 | $0.00 | $1.96 | — | $11.89 |
| 2016 | $5.23 | −$0.08 | $0.09 | $2.83 | — | $16.32 |
| 2017 | $6.01 | $0.53 | $0.09 | $3.68 | — | $18.90 |
| 2018 | $10.45 | $5.96 | $0.04 | $8.03 | — | $27.01 |
| 2019 | $6.09 | $31.85 | $0.13 | −$1.61 | — | $45.61 |
| 2020 | $9.72 | −$0.18 | $0.27 | $2.98 | — | $44.12 |
| 2021 | $14.01 | $3.31 | $0.51 | $4.06 | — | $48.97 |
| 2022 | $11.63 | −$1.98 | $1.06 | $7.11 | — | $35.25 |
| 2023 | $7.40 | $2.94 | $0.20 | $2.59 | — | $39.92 |
| 2024 | $9.14 | −$0.22 | $0.10 | $5.21 | — | $43.46 |
| 2025 | $13.21 | $6.13 | $0.02 | $2.41 | — | $51.44 |
Common questions about Ligand Pharmaceuticals Incorporated
How much does one share of Ligand Pharmaceuticals Incorporated earn?
Over the last 12 months, each share of Ligand Pharmaceuticals Incorporated earned $9.20 of profit on $13.56 of sales, keeping about 68¢ of every $1 (profit margin).
Does Ligand Pharmaceuticals Incorporated pay a dividend?
Ligand Pharmaceuticals Incorporated didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ligand Pharmaceuticals Incorporated’s book value per share?
Ligand Pharmaceuticals Incorporated’s book value is $48.57 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Ligand Pharmaceuticals Incorporated have?
Each share of Ligand Pharmaceuticals Incorporated has $50.54 of cash and investments and $56.56 of debt, as of June 30, 2026.
What is Ligand Pharmaceuticals Incorporated’s free cash flow per share?
$6.13 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Ligand Pharmaceuticals Incorporated bought back shares?
Ligand Pharmaceuticals Incorporated’s share count rose about 8% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.